AF. Hottinger, 2016.
In recent years, advances in the understanding of the regulatory mechanisms of the immune system has led to the development of new approaches for cancer treatment. Currently, immune checkpoint inhibitors are the first successful examples of this approach and several agents that target cytotoxic lymphocyte- associated protein 4 (CTLA-4) and programmed cell death-1 (PD-1) have been approved for various oncologic situations. The aim of this review is to describe the neurologic adverse event profiles for these new immune therapeutic approaches and to discuss their appropriate management.
Hottinger, A. F. (2016). Neurologic complications of immune checkpoint inhibitors. Current Opinion in Neurology, 29(6), 806–812.
Comments